Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Protalix Biotherapeutics, Inc. on August 9, 2012. The filing serves as a Regulation FD disclosure regarding an upcoming investor presentation.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report contains no financial statements or quantitative performance data.
Material Changes
No material changes to financial position or operations are reported in this document. The filing solely announces a scheduled corporate event.
Guidance, Outlook, and Management Commentary
Mr. Yossi Maimon, Vice President and Chief Financial Officer, is scheduled to present at the Canaccord Genuity 32nd Annual Growth Conference on Thursday, August 16, 2012, at 8:30 AM ET. The event will be held at the InterContinental Hotel in Boston, MA. A live webcast will be available on the company's website, with an archived replay available for 30 days post-event.
Key Facts for Investor Verification
- Verify the date and time of the Canaccord Genuity presentation (August 16, 2012, 8:30 AM ET).
- Confirm the availability of the live webcast and archived replay on the company website.
- Note that the press release and this Item 7.01 disclosure are not deemed "filed" for purposes of Section 18 of the Exchange Act.
- Check subsequent filings for any financial guidance or updates provided during the August 16 presentation.